AFM
MYGN icon

Anson Funds Management’s Myriad Genetics MYGN Stock Holding History

Anson Funds Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-504,382
Closed -$3.65M – 155
2025
Q3 		$3.65M Sell
504,382
-841,938
-63% -$5M 0.33% 53
2025
Q2 		$7.15M Buy
+1,346,320
New +$7.95M 1.03% 23

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Anson Funds Management's MYGN Position: Q4 2025 in Review

Anson Funds Management sold out of Myriad Genetics (MYGN) in Q4 2025, closing a stake of 504,382 shares — an estimated $3.65M sold.

Anson Funds Management first reported a position in MYGN in Q2 2025 and held it in 2 quarters. The position peaked at $7.15M in Q2 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2025.

  • Anson Funds Management reported no remaining Myriad Genetics position as of Q4 2025 after selling out during the quarter.
  • Anson Funds Management sold 504,382 Myriad Genetics shares in Q4 2025, an estimated $3.65M.
  • Anson Funds Management first reported a position in Myriad Genetics in Q2 2025 and held it in 2 quarters.
  • Anson Funds Management's Myriad Genetics position peaked at $7.15M in Q2 2025.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2025.

Based on Anson Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.